[go: up one dir, main page]

WO2002059606A3 - Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv - Google Patents

Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv Download PDF

Info

Publication number
WO2002059606A3
WO2002059606A3 PCT/EP2002/000659 EP0200659W WO02059606A3 WO 2002059606 A3 WO2002059606 A3 WO 2002059606A3 EP 0200659 W EP0200659 W EP 0200659W WO 02059606 A3 WO02059606 A3 WO 02059606A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatmnt
epstein
targets
therapeutic agents
virus infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/000659
Other languages
English (en)
Other versions
WO2002059606A2 (fr
Inventor
Bettina Kempkes
Igor Ivanov
Andreas Machl
Georg Bornkamm
Maja Santak
Christian Kappeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Agennix AG
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
GPC Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, GPC Biotech AG filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority to AU2002237287A priority Critical patent/AU2002237287A1/en
Publication of WO2002059606A2 publication Critical patent/WO2002059606A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002059606A3 publication Critical patent/WO2002059606A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/05—Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)

Abstract

Cette invention se rapporte à l'utilisation d'antagonistes et d'inhibiteurs de TRRAP, ATF5, elF1 et SUPT6H comme agents antiviraux, notamment dans le traitement de l'infection par le virus d'Epstein-Barr (EBV) et des maladies associées à une infection à EBV. Des procédés permettant d'identifier ces antagonistes et ces inhibiteurs sont proposés. Cette invention concerne en outre un procédé général permettant l'identification de gènes associés à l'infection par l'identification de gènes dont l'expression est régulée au cours d'une infection.
PCT/EP2002/000659 2001-01-23 2002-01-23 Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv Ceased WO2002059606A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002237287A AU2002237287A1 (en) 2001-01-23 2002-01-23 Targets and therapeutic agents for the treatmnt of epstein-barr virus infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101452 2001-01-23
EP01101452.9 2001-01-23

Publications (2)

Publication Number Publication Date
WO2002059606A2 WO2002059606A2 (fr) 2002-08-01
WO2002059606A3 true WO2002059606A3 (fr) 2003-10-16

Family

ID=8176276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000659 Ceased WO2002059606A2 (fr) 2001-01-23 2002-01-23 Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv

Country Status (2)

Country Link
AU (1) AU2002237287A1 (fr)
WO (1) WO2002059606A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660469A (zh) * 2012-05-31 2012-09-12 哈尔滨工业大学 一种表达植物抗性诱导因子的毕赤酵母基因工程菌株的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032307A1 (fr) * 1994-05-20 1995-11-30 Tularik, Inc. Procede d'immunodetection du facteur de transcription du virus d'epstein-barr
WO1996020723A1 (fr) * 1994-12-30 1996-07-11 Brigham & Women's Hospital Regulation de signaux induits par traf
US6162440A (en) * 1996-02-13 2000-12-19 Johns Hopkins University School Of Medicine EBNA2 peptides and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032307A1 (fr) * 1994-05-20 1995-11-30 Tularik, Inc. Procede d'immunodetection du facteur de transcription du virus d'epstein-barr
WO1996020723A1 (fr) * 1994-12-30 1996-07-11 Brigham & Women's Hospital Regulation de signaux induits par traf
US6162440A (en) * 1996-02-13 2000-12-19 Johns Hopkins University School Of Medicine EBNA2 peptides and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAISER CARMEN ET AL: "Functional genomics in cancer research: Identification of target genes of the Epstein-Barr virus nuclear antigen 2 by subtractive cDNA cloning and high-throughput differential screening using high-density agarose gels.", ELECTROPHORESIS, vol. 20, no. 2, February 1999 (1999-02-01), pages 261 - 268, XP002232293, ISSN: 0173-0835 *

Also Published As

Publication number Publication date
WO2002059606A2 (fr) 2002-08-01
AU2002237287A1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
ATE401079T1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
WO2004006853A3 (fr) Traitement et prevention a l'aide d'agents fixant 4-1bb
WO2000043781A3 (fr) Inhibiteurs de facteurs de differenciation de la croissance et leurs utilisations
ATE429922T1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
WO2004054515A3 (fr) Mimetiques de la thrombopoietine
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
NZ516513A (en) Nitric oxide donors for inducing neurogenesis
GB0130677D0 (en) Medicaments and novel compounds
WO2004004653A3 (fr) Methodes de traitement de la psychose associee a une therapie aux interferon $g(a)
ATE521361T1 (de) Verfahren zur behandlung von gebärmutterhalskrebs
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
WO2003002107A3 (fr) Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques
WO2003004006A8 (fr) Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
WO2004098612A3 (fr) Nouveaux analogues de calcitriol et leur utilisation
WO2004016741A3 (fr) Inhibiteurs de la prenylation contenant du dimethylcyclobutane, leurs methodes de synthese et leur utilisation
WO2002059606A3 (fr) Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv
WO2004037192A3 (fr) Identification et inhibition de cibles anti-mycobacteriennes pour le traitement de maladies infectieuses
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
EP4566667A3 (fr) Traitement d'une maladie cardiométabolique
WO2001083754A3 (fr) Regulateurs cellulaires d'agents infectieux et methodes d'utilisations
DE60223564D1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
WO2004087067A3 (fr) Traitement d'infections par aspergillus a l'aide de thymosine alpha 1
DE60020833D1 (de) Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag
ATE550327T1 (de) Bicyclische iminosäurederivate zur behandlung von (unter anderem) erkrankungen des bewegungsapparates
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP